"Darbackin" .. a possible new treatment for medicine -resistant bacteria

A group of researchers showed the effectiveness of a new antibacterial treatment withdrawn from a modified vehicle known as ‘Darobactin’, which is mainly derived from bacteria. A successful experiments of animals have been effectively proven against drug -resistant bacteria, including Escherichia Coli -resistant bacteria. Anti -bacterial drugs are an important tool in the treatment of infection, but the incidence of bacterial resistance to current medication makes it less effective or even useless in some cases. Antibiotic resistance is one of the largest global health challenges we face today, according to the “World Health Organization”. This dangerous phenomenon arises when bacteria, viruses, fungi and parasites develop over time and can resist the medication designed to eliminate it. As a result, the infection becomes more difficult in treatment, the risk of spreading disease and deaths increases, and the UN organization warns that antibiotic resistance threatens our ability to treat common infectious diseases and we can return to the pre -discovery of antibiotics where infectious diseases were the lives of many people. What is the Darbackein -Antibacterial vehicle? The researchers have discovered the new compound known as ‘Darbackin’ in natural bacteria, and is considered one of the new antibiotics that represents the hope of facing the problem of resistance to traditional antibiotics. This compound is characterized by the ability to combat some types of dangerous bacteria that have developed resistance to existing medicines, making it an important goal for research and development in the field of medicine. Darbackein works by linking with a basic protein found in the cells of some types of bacteria, and this protein is needed for the continuation of the lifespan of bacteria. When “darbackin” is connected to this protein, it disrupts its function, which eventually leads to the death of bacteria, which makes it especially effective against some resistant bacteria, which are often immune to traditional antibiotics. ‘Darbackin’ was initially discovered in the “Photohaddus” bacteria, a type of bacteria that live in the intestines of the thin worms. Average copies of “Darbackin” achieved positive results and after this discovery, researchers began developing modified copies of the vehicle to improve its effectiveness and target specific types of bacteria, and one of these modified copies is known as “D22”, and positive results in laboratory experiences and animals, including their ability to impede the growth of types of bacteria. In provisional experiments, the effectiveness of the “D22” connection has been tested against the “acinetobacter baumannii” use of decorative fish fetuses, and the results have shown a similar effectiveness as an antibiotic known as “Ciprofloxacin” and is an anti -treatment to treat complex infection. Then the researchers moved to experiments on the mice, where the observations indicated that the injection of the “D22” vehicle was more effective than taking it orally. In the activity test against bacteria, the “pseudomonas aeruginosa” infection caused the regular doses of bacteria to grow in the thigh tissue, but the infection was not completely eliminated. Experienced experiences against Escherichia Coli bacteria showed that giving multiple doses of the vehicle eliminated a serious infection in the abdominal cavity during a 25 -hour period. Some doses also showed a remarkable activity, while two daily injections for three days reduced bacteria in a complex infection in the urinary tract, but not the same as the effectiveness of the antibiotic “gentamicin”. The results of the study showed the ability of the “D22” vehicle to impede critical bacterial infection, which emphasizes its potential as an innovative vehicle to counter antibiotic resistance. The researchers emphasized that these results are a first step in developing a property that can be used in future clinical trials.